Evaluating Different Doses of Orelabrutinib in MCL
NCT05978739
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Mantle Cell Lymphoma
Interventions
DRUG:
Orelabrutinib High dose
DRUG:
Orelabrutinib Low dose
Sponsor
InnoCare Pharma Inc.
Collaborators
[object Object]